ANTITUMOR EFFECT ENHANCER USING NEW BIPHENYL COMPOUND Russian patent published in 2022 - IPC C07D207/14 C07D211/58 C07D487/10 C07D487/04 C07D487/08 C07D413/10 C07D403/10 C07D417/10 C07D407/10 A61K31/4523 A61K31/4025 A61K31/403 A61K31/407 A61K31/4192 A61K31/423 A61K31/428 A61K31/4184 A61P35/00 A61P43/00 

FIELD: medicine.

SUBSTANCE: invention relates to the use of a biphenyl compound represented by the formula (I) or its salt for the production of a composition for the prevention and/or treatment of LSD1-related malignant tumor in a cancer patient, where one or more other antitumor agents are administered to the cancer patient, where ring A is a monocyclic, bridging cyclic or spirocyclic 5-10-element nitrogen-containing saturated heterocyclic group having 1-2 nitrogen atoms as heteroatoms; ring B is monocyclic or bicyclic 6-10-element unsaturated hydrocarbon or monocyclic or bicyclic 5-10-element unsaturated heterocyclic group that can be substituted with oxo, which has 1-3 nitrogen atoms, 0-2 oxygen atoms as heteroatoms and which has at least one heteroatom selected from nitrogen and oxygen; R1 is nitro or cyano, R2 is halogen, R3 is amino, mono- or di(C1-C6 alkyl)amino, (C3-C7 cycloalkyl)amino or C1-C6 alkyl, and R4 is halogen, nitro, cyano, substituted or unsubstituted C1-C8 alkyl, substituted C2-C3 alkenyl, unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C7 cycloalkyl, mono- or di(C1-C6 alkyl)amino or unsubstituted carbamoyl; where if at least one R4 is substituted C1-C8 alkyl, substituted C2-C3 alkenyl or substituted C3-C7 cycloalkyl, the substituent is halogen, hydroxy and amino; R5 and R6 can be the same or different, and each is hydrogen or C1-C6 alkyl; R5 and R6 can also form oxo together; if R5 and R6 are the same or different, and each is hydrogen or C1-C6 alkyl, at least one of R5 and R6 is hydrogen; l is an integer from 0 to 2, m is an integer from 0 to 2, and n is an integer from 0 to 3, where if l is 2, two R2 can be the same or different; if m is 2, two R3 can be the same or different; if n is 2-3, from two to three R4 can be the same or different, and where one or more other antitumor agents are at least one selected from cytarabine, azacytidine, decitabine, guadecitabine, daunorubicin, tretinoin (ATRA), RG7388, carboplatin, cisplatin, paclitaxel, irinotecan (SN-38) and etoposide. The invention also relates to the use of the specified biphenyl (I) compound to enhance the antitumor effect of one or more of the other specified antitumor agents in LSD1-associated malignant tumor.

EFFECT: improved antitumor activity of the compound represented by the formula (I), which enhances the antitumor effect when combined with other antitumor agents.

14 cl, 126 tbl, 295 ex